Traub Capital Management LLC Makes New Investment in Novo Nordisk A/S $NVO

Traub Capital Management LLC bought a new stake in Novo Nordisk A/S (NYSE:NVO) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 1,170 shares of the company’s stock, valued at approximately $81,000.

A number of other hedge funds also recently modified their holdings of NVO. Jennison Associates LLC grew its position in shares of Novo Nordisk A/S by 0.3% in the 2nd quarter. Jennison Associates LLC now owns 18,885,343 shares of the company’s stock valued at $1,303,466,000 after purchasing an additional 63,341 shares during the period. Kingstone Capital Partners Texas LLC lifted its stake in Novo Nordisk A/S by 301,443.6% in the second quarter. Kingstone Capital Partners Texas LLC now owns 10,005,216 shares of the company’s stock valued at $690,560,000 after buying an additional 10,001,898 shares in the last quarter. Sustainable Growth Advisers LP boosted its holdings in shares of Novo Nordisk A/S by 11.7% in the second quarter. Sustainable Growth Advisers LP now owns 6,192,636 shares of the company’s stock valued at $427,416,000 after buying an additional 649,390 shares during the period. Goldman Sachs Group Inc. boosted its holdings in shares of Novo Nordisk A/S by 11.3% in the first quarter. Goldman Sachs Group Inc. now owns 5,692,554 shares of the company’s stock valued at $395,291,000 after buying an additional 576,900 shares during the period. Finally, Nuveen LLC bought a new stake in shares of Novo Nordisk A/S during the first quarter worth $370,272,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

NYSE NVO opened at $49.07 on Thursday. The firm has a market capitalization of $219.08 billion, a P/E ratio of 13.48, a price-to-earnings-growth ratio of 2.33 and a beta of 0.65. The company has a current ratio of 0.78, a quick ratio of 0.56 and a debt-to-equity ratio of 0.52. The firm’s fifty day moving average price is $54.20 and its two-hundred day moving average price is $60.61. Novo Nordisk A/S has a 1 year low of $45.05 and a 1 year high of $112.52.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Wednesday, November 5th. The company reported $1.02 earnings per share for the quarter, topping the consensus estimate of $0.77 by $0.25. The company had revenue of $11.74 billion for the quarter, compared to analyst estimates of $11.98 billion. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. Novo Nordisk A/S has set its FY 2025 guidance at EPS. As a group, research analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have issued reports on NVO shares. Barclays reiterated an “equal weight” rating on shares of Novo Nordisk A/S in a report on Wednesday, July 30th. Sanford C. Bernstein upgraded Novo Nordisk A/S from a “market perform” rating to an “outperform” rating in a report on Tuesday, September 9th. Dbs Bank upgraded Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Friday, August 22nd. HSBC set a $70.00 price target on Novo Nordisk A/S in a research report on Wednesday, October 1st. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Novo Nordisk A/S in a research report on Monday. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, nine have assigned a Hold rating and three have given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $59.20.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.